Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32

(PR-inside.com) HONG KONG, Feb 19, 2025 - (ACN Newswire) - Goldman Sachs’ latest report on China’s biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon®, which was recently included in China’s National Reimbursement Drug List (NRDL). The